PT - JOURNAL ARTICLE AU - Ganesh, Suhas AU - Cortes-Briones, Jose AU - Martin, Ashley M. Schnakenberg AU - Skosnik, Patrick D AU - D’Souza, Deepak C AU - Ranganathan, Mohini TI - Delta-9-tetrahydrocannabinol and cannabidiol in psychosis: A balancing act of the principal phyto-cannabinoids on human brain and behavior? AID - 10.1101/2021.05.17.21257345 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.17.21257345 4099 - http://medrxiv.org/content/early/2021/05/19/2021.05.17.21257345.short 4100 - http://medrxiv.org/content/early/2021/05/19/2021.05.17.21257345.full AB - Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the principal phyto-cannabinoids in the cannabis plant. The differential and possibly antagonistic effects of these compounds on specific brain and behavioral responses, and the mechanisms underlying their effects have generated extensive interest in pre-clinical and clinical neuroscience investigations. In this double-blind randomized placebo-controlled counterbalanced human laboratory experiment, we examined the effects of three different dose ratios of CBD: THC (1:1, 2:1 and 3:1) on ‘neural noise’, an electrophysiological biomarker of psychosis known to be sensitive to cannabinoids as well as subjective and psychotomimetic effects. Interestingly, the lowest CBD:THC ratio (1:1) resulted in maximal attenuation of both THC induced psychotomimetic effects (PANSS positive - ATS = 7.83, df = 1, pcorr = 0.015) and neural noise (ATS = 8.83, df = 1, pcorr = 0.009) with an inverse-linear dose response relationship. Further, in line with previous studies, addition of CBD did not reduce the subjective experience of THC induced “high” (p > 0.05 for all CBD doses).These novel results demonstrate that CBD attenuates THC induced subjective and objective effects relevant to psychosis- but in a dose/ratio dependent manner. Given the increasing global trend of cannabis liberalization and application for medical indications, these results assume considerable significance given the potential dose related interactions of these key phyto-cannabinoids.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01180374Funding StatementThis work was supported in part from a grant from NIH (R21 DA030696-01; PI: RanganthanAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale Human Investigations Committee, VA connecticut Healhcare System Human Study SectionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will not be made available at this stage of pre-print publication